16 Jan 2017
Acute myeloid leukaemia study finds personalised therapy is possible
An international collaboration led by clinical researchers at the Wellcome Trust Sanger Institute has shown proof-of-concept that truly personalised therapy will be possible in the future for people with cancer. Details of how a knowledge bank could be used to find the best treatment option for people with acute myeloid leukaemia (AML) are published today (16 January 2017) in Nature Genetics.
11 Jan 2017
Study reveals Spns2 gene as a new drug target
Research led by the Wellcome Trust Sanger Institute has discovered a new biological target for drugs to reduce the spread of tumours in cancer patients. Published in Nature today (11 January 2017), the study with genetically modified mice found 23 genes that are involved in regulating the spread of cancers. The researchers showed that targeting one of these genes – Spns2 – led to a three-quarters reduction in tumour spread.
19 Dec 2016
Based on ground-breaking research at the Wellcome Trust Sanger Institute into the role of the human microbiome in disease. Goal is to create the world’s leading company focused on microbiome biology and its use in medicine. Cambridge Innovation Capital and IP Group co-lead £8m funding round.
Microbiotica has been established to commercialise ground-breaking research, conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute, into the role of the human microbiome in health and disease and its application to medicine. The HMIL is led by Dr Trevor Lawley and collaborates with the Professor Gordon Dougan research group.
19 Dec 2016
International collaboration finds associations with four regions of the genome in PSC patients
Primary Sclerosing Cholangitis (PSC) is a rare disease of the liver with no effective treatment. Researchers identify four regions of the genome associated with the disease, one of which is a potential drug target.
30 Nov 2016
Researchers from the Wellcome Trust Sanger Institute and Imperial College London have developed Microreact, a free, real-time epidemic visualisation and tracking platform that has been used to monitor outbreaks of Ebola, Zika and antibiotic-resistant microbes
Microreact.org is a cloud-based system that combines the power of open data and the web, to provide real-time global data sharing and visualisation, allowing anyone to explore and examine outbreak information with unprecedented speed and detail. In collaboration with the Microbiology Society, any researcher around the world will be able to share their latest information about disease outbreaks.
29 Nov 2016
Two new methods will allow researchers world-wide to rapidly and accurately explore the changing role of genes as the cells develop into tissues such as liver, skin or heart, and discover how this contributes to health and disease.
Wellcome Trust Sanger Institute and University of Cambridge researchers have created sOPTiKO, a more efficient and controllable CRISPR genome editing platform. Today (29 November), in the journal Development, they describe how the freely available single-step system works in every cell in the body and at every stage of development. This new approach will aid researchers in developmental biology, tissue regeneration and cancer.
24 Nov 2016
Company founded on Institute technology goes from strength to strength.
Kymab is a company founded on genetic technologies developed at the Wellcome Trust Sanger Institute by Professor Allan Bradley. Its focus is discovering, developing and delivering new monoclonal antibody medicines to treat a variety of diseases.
23 Nov 2016
In Nature Microbiology, Wellcome Trust Sanger Institute researchers revealed the whole genome of Onchocerca volvulus, and within it key differences to its evolutionary partner in crime
River blindness is a common chronic infectious neglected disease that blights many communities near water in remote areas of the Amazon basin in South America and in Africa. It is caused by the worm Onchocerca volvulus, whose larvae migrate through the body, including into the eyes of infected people, making them blind. The parasite is a major socioeconomic issue in the villages and families it affects because sufferers are no longer able to work. In addition other family members, often children, have to give up their studies or work to care for them, further depriving the family of income or future development.
21 Nov 2016
The UK Prime Minister Rt Hon Theresa May today (21 November) joined key stakeholders from across the life sciences sector to open the Wellcome Trust Sanger Institute’s new Bridget Ogilvie Building and the Biodata Innovation Centre at the Wellcome Genome Campus in Cambridge.
Together these new buildings will house one of the world’s most advanced gene sequencing facilities and a unique innovation space for global genomics and biodata businesses. These buildings will be home to a powerful collaboration between academia, businesses large and small, charities and Government.
17 Nov 2016
As part of BLUEPRINT, Wellcome Trust Sanger Institute led two of the six papers published in the journal Cell
The papers reveal how variation in blood cells’ characteristics and numbers can affect a person’s risk of developing complex diseases such as heart disease, and autoimmune diseases including rheumatoid arthritis, asthma, coeliac disease and type 1 diabetes.